Q-omics provides the consensus-scored GAD2 profile across patient tissues and cancer cell-line models. GAD2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GAD2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, GAD2 protein abundance shows 17,290 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where GAD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAD2 survival associations across molecular data types. GAD2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAD2 RNA expression–survival associations across cancer types. High GAD2 expression shows unfavorable associations in DLBC, LIHC, STAD, UCS and MESO, but favorable associations in UCEC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify UCEC as the clearest survival context for GAD2 RNA expression.
This table summarizes GAD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GAD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAD2 shows lower tumor expression in STAD and higher tumor expression in KIRC, BLCA, BRCA, LUAD and THCA. The KIRC box plot shows higher GAD2 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p < 0.001).
This table shows molecular features associated with GAD2 in patient tissues and cancer cell lines. In patient samples, GAD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GAD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
